{"entity":{"id":"tb-bs1","kind":"drug","name":"TB-Bs1","aka":[],"tldr":"TB-Bs1 is a bispecific antibody from Traverse Biotech that links T cells to tumour cells carrying ROR2, being developed for solid tumours.","summary":"TB-Bs1 is the lead product on the pipeline page of Traverse Biotech: a CD3 by ROR2 bispecific antibody made on the DuoBody platform, for ROR2-positive solid tumours. The company cites published work on ROR2 as a cancer target. No clinical trial is registered.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"Traverse Biotech pipeline","url":"https://www.traversebiotech.com/pipeline-4-1"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["t-cell-engager"],"targets":["cd3"],"drugs":[],"companies":["traverse-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"TB-Bs1","modality":"Bispecific antibody (T-cell engager)","mechanism":"Described by the company as a CD3 by ROR2 DuoBody bispecific antibody: one arm binds CD3 on T cells and the other ROR2 on tumour cells, bringing the two together.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tb-bs1/","neighbours":{"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"traverse-biotech","kind":"company","name":"Traverse Biotech","route":"/companies/traverse-biotech/"}]}}